Technology | Sachi Bio

Transforming discovery with accelerated synthesis, validation, and production of specific nucleic acid therapies.

Cloning-free approach using our platform for rapid target discovery and validation: design, build, test, and learn.
Improved specificity and transport, low off-target effects, multiplexing and multidimensional target validation.

Reversible gene therapy

Unlike other gene-editing technologies, Sachi's Nanoligomer is a revolutionary molecule that can regulate transcription and translation to provide safe and effective therapies

TM

Gain & Loss of function

By using both upregulation and downregulation of gene expression, Nanoligomers have shown programmable path for regulating any gene in any organism

TM

Safe & Effective

Using a six-module functionality and a peptide based chassis, our sequence-specific Nanoligomers

are safe and effective

TM

shutterstock_1114615409-scaled-ou5h7o2wdjydceaew53ppxzatf95lz458fo5z79t9s.jpg

Scalable and high-throughput

Using state-of-the art bioinformatics toolbox and AI tools, we create Nanoligomers to target canonical pathways and upstream regulators to create the best-in-class and first-in-class therapies.

Low-cost scalable chemistry allows synthesis of hundreds of molecules within days.

Using same peptide chassis ensures synthesis of multiple therapeutic molecules in the same manufacturing facility with the need to re-tool. This makes Nanoligomers ideal for Precision and Personalized medicine.

TM

High on-target precision

Nanoligomer design ensures high binding and minimal-off targeting. Dissociation constants (K ) of Nanoligomers are in the nanomolar range. This provides a safe and reliable solution for revolutionary gene therapy.

TM

D

TM

Facile transport

Nanoligomers offer small-molecule like transport, without the need for any lipid encapsulation or special formulation.

Nanoligomers can be directly administered using multiple routes of administration and are shown to be safe and effective in multiple pre-clinical studies.

For treatments being developed against neurodegenerative diseases, Nanoligomer have shown the capability to cross the blood-brain barrier when intended.